Posted by Michael Wonder on 09 Oct 2017
PBS listing opens up a new medication era for leukaemia patients
9 October 2017 - The Leukaemia Foundation welcomes the Federal Government’s announcement today that the cancer medicine, Imbruvica (ibrutinib) will be added to Pharmaceutical Benefits Scheme (PBS).
Mr Bill Petch, CEO at the Leukaemia Foundation said this announcement today is an important step forward for people living with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma in whom the disease has progressed despite treatment with standard therapies.
“This listing will save lives. It means that Australians with CLL who have run out of treatment options can access this new oral therapy which is showing remarkable results. We are another step closer to a time when no one will die from this disease”.
